Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus recommendation of “Hold” from the twenty-one analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $115.00.

A number of research analysts have recently commented on the stock. Evercore ISI upped their price objective on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Barclays increased their price target on shares of Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Cowen reiterated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Finally, Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $134.91 on Thursday. The company has a 50-day moving average price of $113.32 and a 200 day moving average price of $102.00. The company has a market cap of $20.61 billion, a P/E ratio of 30.25, a PEG ratio of 2.36 and a beta of 1.44. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Illumina has a 52 week low of $68.70 and a 52 week high of $153.06.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm earned $1.14 EPS. The business’s revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Research analysts predict that Illumina will post 4.51 earnings per share for the current year.

Insider Activity

In other news, Director Scott Gottlieb acquired 500 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.60% of the company’s stock.

Institutional Trading of Illumina

A number of large investors have recently added to or reduced their stakes in ILMN. Capital World Investors increased its stake in Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. State Street Corp boosted its position in Illumina by 6.8% during the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after purchasing an additional 382,520 shares during the last quarter. WCM Investment Management LLC grew its stake in Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after purchasing an additional 247,460 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after purchasing an additional 78,317 shares in the last quarter. Finally, Corvex Management LP raised its stake in shares of Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after purchasing an additional 2,129,449 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.